Roche ‘steps up’ for gene therapy with $4.3 bn Spark bet
Swiss-based pharma company buying spark as rivals move aggressively into gene therapy
More firms weigh IPOs as biotech fever reaches Europe
Top candidates for a share sale include Swiss firms AC Immune and Molecular Partners
Bubble fears grow amid glut of IPOs in the US by early-stage biotechs
Dicerna Pharmaceuticals a focal point of concern as it has yet to enter clinical trials and refused to impose share sale block on major shareholders
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Stardust
Inquests into the nightclub fire that led to the deaths of 48 people
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices